RJFSA
XBI icon

Raymond James Financial Services Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Raymond James Financial Services Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$21.3M Sell
215,084
-70,955
-25% -$6.97M 0.03% 525
2024
Q2 		$26.5M Sell
286,039
-52,017
-15% -$4.66M 0.04% 417
2024
Q1 		$32.1M Buy
338,056
+83,473
+33% +$7.75M 0.05% 359
2023
Q4 		$22.7M Sell
254,583
-14,376
-5% -$1.07M 0.04% 438
2023
Q3 		$19.6M Sell
268,959
-69,657
-21% -$5.56M 0.04% 459
2023
Q2 		$28.2M Buy
338,616
+81,777
+32% +$6.84M 0.05% 354
2023
Q1 		$19.6M Sell
256,839
-36,695
-13% -$3.04M 0.04% 456
2022
Q4 		$24.4M Buy
293,534
+148,901
+103% +$12.1M 0.05% 369
2022
Q3 		$11.5M Sell
144,633
-118,149
-45% -$9.96M 0.03% 565
2022
Q2 		$19.5M Buy
262,782
+38,635
+17% +$2.9M 0.04% 407
2022
Q1 		$20.1M Sell
224,147
-11,059
-5% -$1.02M 0.04% 446
2021
Q4 		$26.3M Buy
235,206
+120,663
+105% +$14.6M 0.05% 372
2021
Q3 		$14.4M Sell
114,543
-158,231
-58% -$20.4M 0.03% 538
2021
Q2 		$36.9M Buy
272,774
+118,429
+77% +$15.6M 0.08% 266
2021
Q1 		$20.9M Buy
154,345
+14,667
+11% +$2.2M 0.05% 387
2020
Q4 		$19.7M Sell
139,678
-2,849
-2% -$365K 0.05% 356
2020
Q3 		$15.9M Sell
142,527
-139,773
-50% -$15.7M 0.05% 367
2020
Q2 		$31.6M Buy
282,300
+162,329
+135% +$16M 0.1% 211
2020
Q1 		$9.29M Sell
119,971
-3,427
-3% -$303K 0.04% 391
2019
Q4 		$11.7M Buy
123,398
+10,232
+9% +$885K 0.04% 459
2019
Q3 		$8.63M Sell
113,166
-30,465
-21% -$2.53M 0.03% 506
2019
Q2 		$12.6M Sell
143,631
-31,471
-18% -$2.68M 0.05% 394
2019
Q1 		$15.9M Sell
175,102
-17,190
-9% -$1.46M 0.07% 321
2018
Q4 		$13.8M Buy
192,292
+11,720
+6% +$944K 0.07% 293
2018
Q3 		$17.3M Buy
180,572
+10,342
+6% +$1M 0.08% 281
2018
Q2 		$16.2M Buy
170,230
+21,924
+15% +$2.01M 0.08% 273
2018
Q1 		$13M Buy
148,306
+15,421
+12% +$1.41M 0.07% 295
2017
Q4 		$11.3M Sell
132,885
-169,924
-56% -$14.2M 0.07% 318
2017
Q3 		$26.2M Buy
302,809
+62,100
+26% +$4.98M 0.17% 132
2017
Q2 		$18.6M Buy
240,709
+29,346
+14% +$2.08M 0.13% 188
2017
Q1 		$14.7M Buy
211,363
+31,997
+18% +$2.15M 0.11% 218
2016
Q4 		$10.6M Sell
179,366
-8,000
-4% -$494K 0.09% 265
2016
Q3 		$12.4M Buy
187,366
+48,894
+35% +$3.02M 0.11% 226
2016
Q2 		$7.49M Buy
138,472
+123,447
+822% +$6.76M 0.07% 300
2016
Q1 		$776K Buy
15,025
+1,433
+11% +$74.4K 0.01% 1032
2015
Q4 		$954K Sell
13,592
-1,723
-11% -$118K 0.01% 949
2015
Q3 		$953K Buy
+15,315
New +$1.21M 0.02% 790

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Raymond James Financial Services Advisors's XBI Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 25% in Q3 2024, selling an estimated $6.97M and leaving 215,084 shares worth $21.3M. The position accounts for 0.03% of the portfolio, ranked #525.

Raymond James Financial Services Advisors first reported a position in XBI in Q3 2015 and has held it in 37 quarters since. The position peaked at $36.9M in Q2 2021. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

  • Raymond James Financial Services Advisors held 215,084 shares of State Street SPDR S&P Biotech ETF worth $21.3M as of Q3 2024.
  • Raymond James Financial Services Advisors sold 70,955 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $6.97M.
  • State Street SPDR S&P Biotech ETF made up 0.03% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #525 holding.
  • Raymond James Financial Services Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2015 and has held it in 37 quarters since.
  • Raymond James Financial Services Advisors's State Street SPDR S&P Biotech ETF position peaked at $36.9M in Q2 2021.
  • 769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.